From: Pelvic exenteration in gynecologic cancer: complications and oncological outcome
Presentation of disease [n (%)] | |
First diagnosis | 2 (9) |
Relapse | 19 (82) |
Persistence | 2 (9) |
Age [Mean ± SD (range)] | 57.8 ± 12.4 (29–84) |
BMI [Mean ± SD (range)] | 27.4 ± 7.1 (17–50) |
Menopausal status [n (%)] | |
Pre | 17 (74) |
Post | 6 (26) |
ECOG performance status [n (%)] | |
0 | 20 (87) |
1 | 2 (9) |
2 | 1 (4) |
Comorbidity [n (%)] | |
None | 15 (65) |
Hypertension | 5 (22) |
Diabetes mellitus | 5 (22) |
Hypercholesterolemia | 1 (4) |
Monorenal | 1 (4) |
Primary tumour origin [n (%)] | |
Vulvar cancer | 9 (39) |
Cervix cancer | 11 (48) |
Endometrial cancer | 3 (13) |
Previous treatment [n (%)] | |
None | 3 (13) |
RT | 4 (17) |
ChT | 0 (0) |
RT + ChT | 16 (70) |
Previous oncological surgery [n (%)] | |
No | 5 (22) |
Yes | 18 (78) |
ASA score [n (%)] | |
1 | 1 (4) |
2 | 18 (78) |
3 | 4 (17) |
Operative intention [n (%)] | |
Curative | 21 (91) |
Palliative | 2 (9) |